Treating rats with a combination of bevacizumab and cilengitide significantly restricted tumor invasion than with bevacizumab only, suggesting that inhibiting ITGA5 could replenish the antitumor ability of anti-VEGF agents (55). The gene discussed is ITGA5; the disease is neoplasm.